Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioAlliance Pharma
Paris, Francebioalliancepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Livatag® showed a significant survival increase (~17 months additional survival vs. control group) in advanced hepatocellular carcinoma patients during phase II trials, leading to a phase III trial initiation. Loramyc®/Oravig®, targeting oropharyngeal candidiasis, was registered/commercialized in multiple countries. Sitavig®, based on acyclovir Lauriad®, was registered for herpes labialis. AMEP biotherapy showed promising preliminary results in metastatic melanoma.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculeNanoparticleBiologic
- Industry
- Biotech
02
Partnerships
Vestiq Pharmaceutical (US commercialization partner for Oravig)Sosei and Fujifilm Pharma (Japan development/commercialization partners)
Beyond the preview
Go deeper on BioAlliance Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioAlliance Pharma.